Microbot Medical Inc. announced the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endov vascular Robotic Surgical System.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | +1.87% | -4.39% | -33.54% |
Jun. 11 | Microbot Medical Files Common Stock Registration Statement | MT |
Jun. 03 | Sector Update: Health Care Stocks Gain Late Afternoon | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.54% | 17.08M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met